Isocitrate dehydrogenase mutations: new opportunities for translational research
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Over the last decade, comprehensive genome-wide sequencing studies have enabled us to find out unexpected genetic alterations of metabolism in cancer. An example is the identification of arginine missense mutations of isocitrate dehydrogenases-1 and -2 (IDH1/2) in glioma, acute myeloid leukemia (AML), chondrosarcomas, and cholangiocarcinoma. These alterations are closely associated with the production of a new stereospecific metabolite, (R)-2-hydroxyglutarate (R-2HG). A large number of follow-up studies have been performed to address the molecular mechanisms of IDH1/2 mutations underlying how these events contribute to malignant transformation. In the meanwhile, the development of selective mutant IDH1/2 chemical inhibitors is being actively pursued in the scientific community and pharmaceutical industry. The present review article briefly discusses the important findings that highlight the molecular mechanisms of IDH1/2 mutations in cancer and provides a current status for development of selective mutant IDH1/2 chemical inhibitors.
Abstract
Over the last decade, comprehensive genome-wide sequencing studies have enabled us to find out unexpected genetic alterations of metabolism in cancer. An example is the identification of arginine missense mutations of isocitrate dehydrogenases-1 and -2 (IDH1/2) in glioma, acute myeloid leukemia (AML), chondrosarcomas, and cholangiocarcinoma. These alterations are closely associated with the production of a new stereospecific metabolite, (R)-2-hydroxyglutarate (R-2HG). A large number of follow-up studies have been performed to address the molecular mechanisms of IDH1/2 mutations underlying how these events contribute to malignant transformation. In the meanwhile, the development of selective mutant IDH1/2 chemical inhibitors is being actively pursued in the scientific community and pharmaceutical industry. The present review article briefly discusses the important findings that highlight the molecular mechanisms of IDH1/2 mutations in cancer and provides a current status for development of selective mutant IDH1/2 chemical inhibitors.
참고문헌 (32)
- Warburg O, "On the origin of cancer cells", Science, 123, pp.309~314 (1956)
- Vogelstein B, "Cancer genome landscapes", Science, 339, pp.1546~1558 (2013)
- Luo W, "Emerging roles of PKM2 in cell metabolism and cancer progression", Trends Endocrinol Metab, 23, pp.560~566 (2012)
- Teicher BA, "Targeting cancer metabolism", Clin Cancer Res, 18, pp.5537~5545 (2012)
- Dang L, "IDH mutations in glioma and acute myeloid leukemia", Trends Mol Med, 16, pp.387~397 (2010)
- Parsons DW, "An integrated genomic analysis of human glioblastoma multiforme", Science, 321, pp.1807~1812 (2008)
- Sanson M, "Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas", J Clin Oncol, 27, pp.4150~4154 (2009)
- Yan H, "IDH1 and IDH2mutations in gliomas", N Engl J Med, 360, pp.765~773 (2009)
- Bleeker FE, "IDH1 mutations at residue p. R132(IDH1(R132))occur frequently in high-grade gliomas but not in other solid tumors", Hum Mutat, 30, pp.7~11 (2009)
- Xu X, "Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity", J Biol Chem, 279, pp.33946~33957 (2004)
- Oermann EK, "Alterations of metabolic genes and metabolites in cancer", Semin Cell Dev Biol, 23, pp.370~380 (2012)
- Watanabe T, "IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas", Am J Pathol, 174, pp.1149~1153 (2009)
- Losman JA, "What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer", Genes Dev, 27, pp.836~852 (2013)
- Schwartzentruber J, "Driver mutations in histone H3. 3 and chromatin remodelling genes in paediatric glioblastoma", Nature, 482, pp.226~231 (2012)
- Pollard PJ, "Cancer. Puzzling patterns of predisposition", Science, 324, pp.192~194 (2009)
- Zhao S, "Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha", Science, 324, pp.261~265 (2009)
- Dang L, "Cancer-associated IDH1 mutations produce 2-hydroxyglutarate", Nature, 462, pp.739~744 (2009)
- Cairns RA, "Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities", Cancer Discov, 3, pp.730~741 (2013)
- Andronesi OC, "Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate", J Clin Invest, 123, pp.3659~3663 (2013)
- Sasaki M, "D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function", Genes Dev, 26, pp.2038~2049 (2012)
- Sasaki M, "IDH1(R132H)mutation increases murine haematopoietic progenitors and alters epigenetics", Nature, 488, pp.656~659 (2012)
- Kitamura T, "Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin", J Cell Physiol, 140, pp.323~334 (1989)
- Losman JA, "(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible", Science, 339, pp.1621~1625 (2013)
- Kranendijk M, "Evidence for genetic heterogeneity in D-2-hydroxyglutaric aciduria", Hum Mutat, 31, pp.279~283 (2010)
- Struys EA, "Mutations in the D-2-hydroxyglutarate dehydrogenase gene cause D-2-hydroxyglutaric aciduria", Am J Hum Genet, 76, pp.358~360 (2005)
- Kranendijk M, "IDH2 mutations in patients with D-2-hydroxyglutaric aciduria", Science, 330, pp.336~ (2010)
- Rohle D, "An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells", Science, 340, pp.626~630 (2013)
- Wang F, "Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation", Science, 340, pp.622~626 (2013)
- Popovici-Muller J, "Discovery of the First Potent Inhibitors of Mutant IDH1That Lower Tumor 2-HG in Vivo", ACS Med Chem Lett, 3, pp.850~855 (2012)
- Davis MI, "Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1", J Biol Chem, 289, pp.13717~13725 (2014)
- Liu Z, "Inhibition of cancerassociated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity", J Med Chem, 57, pp.8307~8318 (2014)
- Deng G, "Selective Inhibition of Mutant Isocitrate Dehydrogenase 1(IDH1)via Disruption of a Metal Binding Network by an Allosteric Small Molecule", J Biol Chem, 290, pp.762~774 (2015)